Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison
Open Access
- 3 February 2011
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 25 (6) , 744-754
Abstract
The aim of this study was to investigate the long-term effectiveness and efficacy of haloperidol, risperidone and olanzapine in first-episode schizophrenia-spectrum disorders. This was a prospective, randomized, open-label study. Data for the present investigation were obtained from a large epidemiological and 3-year longitudinal intervention programme of first-episode psychosis conducted at the University Hospital Marques de Valdecilla, Santander, Spain. One hundred and seventy-four patients were randomly assigned to haloperidol ( N = 56), olanzapine ( N = 55), or risperidone ( N = 63) and followed up for 1 year. The primary effectiveness measure was all causes of treatment discontinuation. Effectiveness analyses were based on intend-to-treat populations. In addition, an analysis based on per protocol populations was conducted in the analysis for clinical efficacy. The treatment discontinuation rate for any cause was higher with haloperidol than with risperidone and olanzapine (χ2 = 8.517; p = 0.014). The difference in discontinuation rate between risperidone and olanzapine was not significant (χ2 = 0.063; p = 0.802). There were no significant advantages of any of the three treatments in reducing the severity of psychopathology. Risperidone and olanzapine demonstrated higher effectiveness relative to haloperidol, but the three antipsychotics were equally effective in reducing the severity of psychopathology. Specific clinical programmes and the use of second-generation antipsychotics may enhance the effectiveness of antipsychotic treatments.Keywords
This publication has 34 references indexed in Scilit:
- Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialThe Lancet, 2008
- Maintenance Treatment With Risperidone or Low-Dose Haloperidol in First-Episode SchizophreniaThe Journal of Clinical Psychiatry, 2007
- A Practical Clinical Trial Comparing Haloperidol, Risperidone, and Olanzapine for the Acute Treatment of First-Episode Nonaffective PsychosisThe Journal of Clinical Psychiatry, 2006
- Olanzapine and haloperidol in first episode psychosis: Two-year dataSchizophrenia Research, 2006
- The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trialSchizophrenia Research, 2005
- Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter StudySchizophrenia Bulletin, 1999
- The World Health Organization Short Disability Assessment Schedule (WHO DAS-S): a tool for the assessment of difficulties in selected areas of functioning of patients with mental disordersSocial Psychiatry and Psychiatric Epidemiology, 1996
- Assessing Depression in Schizophrenia: The Calgary Depression ScaleThe British Journal of Psychiatry, 1993
- A Rating Scale for Drug-Induced AkathisiaThe British Journal of Psychiatry, 1989
- ECDEU Assessment Manual1976